OBJECTIVES The aim of this study was to compare the stroke/death rates between proximal embolic protection devices (P-EPDs) and distal filter embolic protection devices (F-EPDs) in elective carotid artery stenting (CAS).
A P-EPD may be theoretically superior to an F-EPD for stroke prevention because the carotid lesion is never touched in an unprotected fashion when using a P-EPD. Three small single-center studies demonstrated significantly fewer surrogate events, such as transcranial Doppler-detected microembolic signals and diffusion-weighted magnetic resonance imaging (dwMRI) lesions with the use of P-EPDs (3) (4) (5) . No largescale analysis using the clinical outcomes of stroke and mortality has yet been performed to evaluate the potential utility of P-EPDs compared with F-EPDs. In the current study, we sought to compare outcomes of CAS using F-EPDs and P-EPDs in a large, nationally representative, multi-institutional registry. Patients for whom no embolic protection was attempted were excluded as well (n ¼ 278, 2.6%). Outcomes in these patients were reported previously and were not directly relevant to the present analysis (1).
OUTCOMES. The primary outcome of interest was the occurrence of in-hospital major adverse events, Giri et al.
Proximal Versus Distal EPD for CAS STATISTICAL ANALYSIS. We performed unadjusted comparisons of characteristics for patients for whom F-EPDs were used versus those for whom P-EPDs were used, using the Student t test for continuous variables and the chi-square test for categorical variables. Values are mean AE SD or n (%). Continuous variables compared using 1-way analysis of variance. Categorical variables compared using the chi-square or Fisher exact test.
CAS ¼ carotid artery stenting; CCS ¼ Canadian Cardiovascular Society; CEA ¼ carotid endarterectomy; F-EPD ¼ distal filter embolic protection; ICD ¼ implantable cardioverter-defibrillator; MI ¼ myocardial infarction; NYHA ¼ New York Heart Association; P-EPD ¼ proximal embolic protection.
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To account for nonrandom treatment assignment to the devices being compared, we used propensityscore matching. Specifically, we used logistic regression to estimate the log odds of undergoing CAS with a P-EPD or an F-EPD for each patient, on the basis of the 40 variables discussed earlier. We then conducted 1:4 nearest-neighbor matching for each of the 590 patients in the P-EPD group to maximize the power of the sample. We used a caliper width of 0.2 times the SD of the logit of the propensity score. Compared with logistic regression, this propensity matching model allows for more complete risk adjustment when the number of events in any group is low, as well as proper assessment of balance of measured confounders before analysis (8, 9) . Standardized differences between matched groups were estimated for all covariates, and differences of <10 were considered evidence of the accepted threshold for successful matching (10) . Outcomes between matched groups were then compared using conditional logistic regression. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
A P-EPD was used in a total of 590 of 10,246 cases Table 1 ).
In the overall population studied, the in-hospital stroke/death rate was 2.6% and the in-hospital stroke rate was 2.2%. In unadjusted analyses, the inhospital stroke/death rates in those treated with a P-EPD and an F-EPD were similar (1.5% vs. 2.4%, Table 2) . For the 75.1% of patients with 30-day follow-up data available (n ¼ 7,693), the stroke/death rates between the groups remained similar (2.5% vs. 4.2%, p ¼ 0.07) ( Table 2) Table 2 ).
There was no difference in the ipsilateral stroke rate between the groups (0.8%% vs. 1.0%, p ¼ 0.62) ( Table 3) . For the 76.5% of matched patients with 30-day follow-up data available (n ¼ 1,875), differences in stroke/death rates between the groups remained nonsignificant (2.7% vs. 4.0%, p ¼ 0.22) ( Table 2) .
When the definition of stroke was broadened to include patients with documented changes in preand post-NIHSS scores of $2, no significant differences were found between the matched groups for in-hospital stroke rate (2.0% vs. 2.7%, p ¼ 0.42).
No difference in treatment effect of P-EPDs versus F-EPDs was observed in symptomatic compared with asymptomatic patients (p value for interaction ¼ 0.60 for in-hospital stroke or death; p value for interaction ¼ 0.66 for 30-day stroke or death).
DISCUSSION
In this first large, multicenter, comparative effectiveness analysis of proximal versus distal embolic protection for CAS, we found that P-EPDs have been used in a small minority of U.S. patients. P-EPDs and F-EPDs were associated with similar periprocedural Values are n (%).
Abbreviations as in Table 1 .
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and 30-day risks of stroke/death in both unadjusted and propensity-matched analyses.
Four previous randomized trials reported on the surrogate outcomes of new dwMRI lesions or transcranial Doppler-detected microembolic signals after P-EPD and F-EPD use (3) (4) (5) 11) . Three of these studies noted fewer new dwMRI lesions or microembolic signals in patients treated with P-EPD, Additionally, we did not observe reduced rates of ipsilateral stroke with P-EPDs, the major presumed benefit of P-EPD use. It should be noted, however, that no signal of harm was noted with the use of P-EPDs, and there were trends toward improved outcomes at 30 days that did not meet statistical significance. As such, it is reasonable to defer to operator preference, experience, and judgment in specific clinical scenarios when choosing the type of embolic protection for an individual CAS procedure.
Because of the slow adoption of P-EPDs in the United States, the proximal protection group in this study was much smaller than the F-EPD group. We attempted to account for any selection bias with our propensity-matched analysis. Still, we cannot rule out the influence of unmeasured confounders in this analysis. These include operator experience, operator specialty, and anatomic characteristics (e.g., external carotid artery stenosis precluding effective proximal protection device placement) that may have biased the choice of protection device. Next, it is possible that operators were less familiar with P-EPD, implying that the currently observed stroke rates in P-EPD-treated patients may decrease over time.
However, in an analysis of the first 295 procedures performed with P-EPDs versus the second 295 procedures performed, there were no significant differences in stroke rates (data not shown). Finally, despite being the largest national registry of CAS, the number of P-EPD devices used in the registry was modest, and the study may be underpowered to detect potentially meaningful differences in outcomes between the devices. However, given the rates of the primary endpoint observed in our cohort, a randomized trial of >34,000 subjects would be required to detect a significant difference between PEPDs and F-EPDs with 80% power (a trial with a design on the basis of our observed 30-day event rates would require >6,000 patients). There are no known plans to organize such an effort, so it is likely that the current data will remain the best available evidence on this issue for the foreseeable future.
CONCLUSIONS
Use of a P-EPD during CAS was associated with similarly low rates of in-hospital stroke/death compared with F-EPD use in the first comparative analysis performed of this issue. An adequately powered randomized trial comparing clinical outcomes between these devices is unlikely to be feasible.
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PERSPECTIVES P-EPDs have theoretical advantages that may make them superior to distal F-EPDs for stroke prevention during CAS. In more than 10,000 patients treated with embolic protection for CAS, the use of P-EPDs was associated with low rates of in-hospital stroke/ death similar to those with F-EPDs. Given the observed low event rates in the current analysis, an adequately powered randomized trial examining this issue is unlikely to be feasible. 
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